Aratana Therapeutics (PETX) Tops Q3 EPS by 10c

Aratana Therapeutics (NASDAQ: PETX) reported Q3 EPS of ($0.38), $0.10 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $40 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• InspireMD (NSPR) Tops Q2 EPS by 1c
• BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c